ABBOTT REPORTS THIRD-QUARTER RESULTS

We're adding to our more than decade-long streak of meeting or beating Wall Street expectations.

Abbott Reports Third-Quarter Results

Oct 17 2018

Results are in – and thanks to a strong product pipeline and outstanding execution, we’ve again added to our more than decade-long streak of meeting or beating Wall Street expectations.

For the quarter, Abbott delivered impressive sales and double-digit earnings-per-share growth.

All four of our businesses (Diagnostics, Devices, Nutrition and Medicines) contributed to strong growth in the quarter, and we announced plans to narrow our outlook for the rest of the year.

Fueling these results is Abbott’s highly productive product pipeline – including significant recent advancements in Diabetes, Structural Heart and Diagnostics.

Our latest performance is a reflection of Abbott’s commitment to sustainable organic growth. Abbott’s stock has nearly doubled since January 2017, and during the last year, we have averaged more than 7 percent organic sales growth – a true differentiator for a company our size.

Some of the product highlights from the quarter include:

  • FreeStyle® Libre 14 day system, is now the longest lasting self-applied glucose sensor approved in the United States.
  • FreeStyle® Libre 2 system, which utilizes Bluetooth technology and offers optional real-time glucose alarms, was approved in Europe.
  • MitraClip® NTR and MitraClip® XTR, the latest versions of our leading heart valve repair device, are now approved in the United States.
  • Positive results from the landmark COAPT study demonstrated MitraClip improved survival and clinical outcomes for select patients with secondary mitral regurgitation. Data is expected to support an expanded indication for MitraClip.
  • High Sensitive Troponin-I, a test indicated to help predict the chances of a heart attack potentially up to month to years in advance, is available for use in Europe.

For full financials, you can read our press release, or take a look at some additional materials below:

Abbott's Chairman and CEO Miles D. White shared his views on third-quarter performance:

 
 

 

Learn more about Abbott’s third-quarter 2018 results:

 
 

 

Download a summary of Abbott's earnings highlights here.

For more information on Abbott's earnings results, see the news release.

 

INDICATIONS AND IMPORTANT SAFETY INFORMATION
FreeStyle Libre and FreeStyle Libre 14 day Flash Glucose Monitoring systems are continuous glucose monitoring (CGM) devices indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The systems are intended for single patient use and require a prescription.

CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.

WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The systems do not have alarms unless the sensor is scanned, and the systems contain small parts that may be dangerous if swallowed. The systems are not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes.

Review all product information before use or contact Abbott Toll Free (855-632-8658) (or visit www.freestylelibre.us) for detailed indications for use and safety information. For full indications for use and safety information, see more here.

true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?